VPC
LYEL icon

Vestal Point Capital’s Lyell Immunopharma LYEL Stock Holding History

Vestal Point Capital’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,500
Closed -$290K – 71
2024
Q1 		$290K Buy
+6,500
New +$278K 0.02% 58

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's LYEL Position: Q2 2024 in Review

Vestal Point Capital sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 6,500 shares — an estimated $290K sold.

Vestal Point Capital first reported a position in LYEL in Q1 2024 and held it in 1 quarter. The position peaked at $290K in Q1 2024. 119 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Vestal Point Capital reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Vestal Point Capital sold 6,500 Lyell Immunopharma shares in Q2 2024, an estimated $290K.
  • Vestal Point Capital first reported a position in Lyell Immunopharma in Q1 2024 and held it in 1 quarter.
  • Vestal Point Capital's Lyell Immunopharma position peaked at $290K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.